Compare EVO & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | PEB |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | Germany | United States |
| Employees | 4766 | 60 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.2M | 1.5B |
| IPO Year | N/A | N/A |
| Metric | EVO | PEB |
|---|---|---|
| Price | $2.42 | $11.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 10 |
| Target Price | $7.00 | ★ $12.45 |
| AVG Volume (30 Days) | 105.5K | ★ 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.35% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.13 | $2.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $7.41 |
| 52 Week High | $4.80 | $13.35 |
| Indicator | EVO | PEB |
|---|---|---|
| Relative Strength Index (RSI) | 27.25 | 44.33 |
| Support Level | N/A | $11.93 |
| Resistance Level | $3.78 | $12.91 |
| Average True Range (ATR) | 0.10 | 0.47 |
| MACD | -0.10 | -0.14 |
| Stochastic Oscillator | 8.81 | 23.46 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.